2015 ASCO Journal Club: Hematologic Malignancies Third Quarter

Each quarter, ASCO’s experts review the leading journals, including the Journal of Clinical Oncology, to compile the most relevant, practice-changing science in Hematological Malignancies. Reviews are presented in a didactic slide format, with audio commentary and links to references and resources and will focus on the following areas: translational science, clinical trials, reviews, guidelines, and editorials.

Articles covered in this quarter’s review include:

  • Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).  Mamot C, et al. J Clin Oncol. 2015; Epub Jul 6.
  • Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.  Casulo C, et al. J Clin Oncol. 2015; Epub Jun 29
  • Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.  O’Connor OA, et al. J Clin Oncol. 2015; Epub Jun 22.

Learning Objectives

  • Explain the role of histone deacetylases inhibitor as new targeted therapy for T cell lymphoma
  • Recognize treatment of relapse of T cell lymphoma is an unmet need with median survival of six months
  • Incorporate new drugs for a better management of peripheral T cell lymphomas
  • Apply knowledge learned to enhance the care delivered to patients with hematologic malignancies
Continuing Education Credit
1 Credit/Point is available for participation in this course. Certificate and credit types available include:
  • AMA PRA Category 1 Credits™
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred. 

Important Notes

  • This course expires on September 30, 2018. Participants must complete all necessary course components by this date to receive credit.